We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03021018
Recruitment Status : Recruiting
First Posted : January 13, 2017
Last Update Posted : December 5, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Brivaracetam Drug: Lorazepam Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Actual Study Start Date : February 6, 2017
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy Seizures
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Brivaracetam (BRV) 100 mg
Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
Drug: Brivaracetam
  • Pharmaceutical Form: Solution for infusion
  • Concentration: 10 mg/ml
  • Route of Administration: intravenous
Other Name: Briviact
Experimental: Brivaracetam (BRV) 200 mg
Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
Drug: Brivaracetam
  • Pharmaceutical Form: Solution for infusion
  • Concentration: 10 mg/ml
  • Route of Administration: intravenous
Other Name: Briviact
Active Comparator: Lorazepam (LZP)
Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
Drug: Lorazepam
  • Pharmaceutical Form: Solution for injection
  • Route of Administration: intravenous


Outcome Measures

Primary Outcome Measures :
  1. Time to next seizure (per clinical observation with electroencephalogram [EEG] confirmation) or rescue medication [ Time Frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2) ]
    This variable is calculated in hours.


Secondary Outcome Measures :
  1. Time to next seizure (per clinical observation) or rescue medication [ Time Frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2) ]
    This variable is calculated in hours.

  2. Proportion of subjects who are seizure-free per clinical observation at 6 hours after the end of study drug administration [ Time Frame: At 6 hours after the end of study drug administration ]
    This variable is defined as the number of subjects seizure free during 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat (ITT) set.

  3. Proportion of subjects who are seizure-free per clinical observation at 8 hours after the end of study drug administration [ Time Frame: At 8 hours after the end of study drug administration ]
    This variable is defined as the number of subjects seizure free during 8 hours after the end of study drug administration divided by the number of subjects in the ITT set.

  4. Proportion of subjects who are seizure-free per clinical observation at 12 hours after the end of study drug administration [ Time Frame: At 12 hours after the end of study drug administration ]
    This variable is defined as the number of subjects seizure free during 12 hours after the end of study drug administration divided by the number of subjects in the ITT set.

  5. Proportion of subjects who receive rescue medication during the 6 hours after the end of study drug administration [ Time Frame: During the 6 hours after the end of study drug administration ]
    This variable is defined as the number of subjects who received rescue medication with start date and time within the first 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat as randomized (ITT-R) set.

  6. Proportion of subjects who receive rescue medication during the 8 hours after the end of study drug administration [ Time Frame: During the 8 hours after the end of study drug administration ]
    This variable is defined as the number of subjects who received rescue medication with start date and time within the first 8 hours after the end of study drug administration divided by the number of subjects in the ITT-R set.

  7. Proportion of subjects who receive rescue medication during the 12 hours after the end of study drug administration [ Time Frame: During the 12 hours after the end of study drug administration ]
    This variable is defined as the number of subjects who received rescue medication with start date and time within the first 12 hours after the end of study drug administration divided by the number of subjects in the ITT-R set.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is male or female, 18 to 70 years of age, inclusive
  • Subject has an established diagnosis of epilepsy
  • Subject has been admitted to the institution's Epilepsy Monitoring Unit (EMU) for seizure characterization or noninvasive presurgical evaluation or such admission is planned within 21 days of Screening

Exclusion Criteria:

  • Subject has previously participated in this study and was treated with study drug. Re-screen is permitted
  • Subject has participated in another study of an investigational medicinal product (IMP) or a medical device within the previous 30 days of Epilepsy Monitoring Unit (EMU) admission or is currently participating in another study of an IMP or a medical device
  • Subject has taken brivaracetam (BRV) or Levetiracetam (LEV) in the 21 days prior to EMU admission
  • History or presence of status epilepticus during the 6 months prior to EMU admission
  • Subject has a medical or psychiatric condition that in the opinion of the Investigator could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has > 2x upper limit of normal (ULN) of any of the following: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or > ULN total bilirubin
  • Subject has chronic liver disease
  • Subject has hypersensitivity to BRV or any of its excipients
  • Subject has a history of alcohol or drug abuse during the 6 months prior to EMU admission
  • Subject with a history of psychogenic seizures
  • Subject is a pregnant or lactating female
  • Subject has a history of a significant Adverse Event (AE) due to a benzodiazepine in the opinion of the Investigator
  • Subject has respiratory failure (or is at risk for respiratory failure), untreated sleep apnea, or other severe cardiorespiratory disease with New York Heart Association Class III or IV functional status, or requires supplemental oxygen
  • Subject has acute narrow-angle glaucoma or myasthenia gravis
  • Subject is receiving benzodiazepine treatment (defined as an average of >=4 administrations per week) that started less than 28 days prior to EMU admission
  • Subject has a known allergic reaction or intolerance to benzodiazepines or benzodiazepine excipients
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03021018


Contacts
Contact: UCB Cares +1844599 ext 2273 UCBCares@ucb.com

Locations
United States, Alabama
Ep0087 108 Recruiting
Birmingham, Alabama, United States, 35294
United States, Arizona
Ep0087 104 Recruiting
Phoenix, Arizona, United States, 85013
Ep0087 117 Recruiting
Tucson, Arizona, United States, 85724
United States, Connecticut
Ep0087 110 Recruiting
New Haven, Connecticut, United States, 06510
United States, Florida
Ep0087 112 Recruiting
Orlando, Florida, United States, 32806
United States, Illinois
Ep0087 115 Recruiting
Chicago, Illinois, United States, 60611
Ep0087 113 Recruiting
Chicago, Illinois, United States, 60612
Ep0087 122 Withdrawn
Chicago, Illinois, United States, 60637
United States, Kansas
Ep0087 119 Recruiting
Wichita, Kansas, United States, 67214
United States, Massachusetts
Ep0087 116 Recruiting
Belmont, Massachusetts, United States, 02478
Ep0087 103 Recruiting
Boston, Massachusetts, United States, 02111
Ep0087 106 Recruiting
Boston, Massachusetts, United States, 02215
United States, Michigan
Ep0087 107 Recruiting
Detroit, Michigan, United States, 48201
United States, New Hampshire
Ep0087 101 Recruiting
Lebanon, New Hampshire, United States, 03756
Ep0087 125 Recruiting
Lebanon, New Hampshire, United States, 03756
United States, New York
Ep0087 120 Recruiting
Rochester, New York, United States, 14642
United States, North Carolina
Ep0087 121 Recruiting
Chapel Hill, North Carolina, United States, 27599
Ep0087 105 Recruiting
Charlotte, North Carolina, United States, 28204
Ep0087 111 Withdrawn
Durham, North Carolina, United States, 27705
United States, Pennsylvania
Ep0087 123 Recruiting
Hershey, Pennsylvania, United States, 17033-2360
United Kingdom
Ep0087 118 Recruiting
Houston, Texas, United Kingdom, 77030
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
Investigators
Study Director: UCB Cares UCB (+1 844 599 2273)
More Information

Responsible Party: UCB Biopharma S.P.R.L.
ClinicalTrials.gov Identifier: NCT03021018     History of Changes
Other Study ID Numbers: EP0087
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: December 5, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
Epilepsy
Brivaracetam
Epilepsy Monitoring Unit
Increased seizure activity

Additional relevant MeSH terms:
Anticonvulsants
Epilepsy
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Brivaracetam
Lorazepam
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action